Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 5/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21621090 | 0.86 | SCN9A (0.42) | XPO1PIM1PIM2KDM4ELMNA | |
| SCHEMBL21617070 | 0.83 | XPO1 (0.42) | XPO1PIM1PIM2KDM4ELMNA | |
| SCHEMBL30764783 | 0.83 | XPO1 (0.42) | XPO1PIM1PIM2KDM4ELMNA | |
| SCHEMBL21617090 | 0.83 | XPO1 (0.43) | XPO1PIM1PIM2RAPGEF4KDM4E | |
| SCHEMBL21621122 | 0.83 | XPO1 (0.43) | XPO1PIM1PIM2RAPGEF4KDM4E | |
| SCHEMBL21621091 | 0.81 | KDR (0.41) | XPO1KDM4ETP53ALDH1A1HTT | |
| SCHEMBL30764789 | 0.81 | KDR (0.41) | XPO1KDM4ETP53ALDH1A1HTT | |
| SCHEMBL21617050 | 0.81 | SCN9A (0.50) | XPO1KDM4ERAB9AKMT2ATDP1 | |
| SCHEMBL21617057 | 0.81 | NCF1 (0.46) | KDM4ELMNAHPGDALDH1A1HSD17B10 | |
| SCHEMBL30764829 | 0.81 | NCF1 (0.46) | KDM4ELMNAHPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035348-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2026-02-05 | — | — | US | disclosed |
| US-12479802-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-11-25 | — | — | US | disclosed |
| US-20240308964-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2024-09-19 | — | — | US | disclosed |
| US-12084422-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ABIVAX (FR) | 2024-09-10 | — | — | US | disclosed |
| CN-112566899-B | phenyl-N-quinoline derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20210309611-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-10-07 | — | — | US | disclosed |
| US-20210309611-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-10-07 | — | — | US | disclosed |
| EP-3820852-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-05-19 | — | — | EP | disclosed |
| CN-112566899-A | phenyl-N-quinoline derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2020011810-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011810-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308964-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ORC3, NSUN3, POLR2H | XPO1 2079/4885PIM1 3536/4885PIM2 3862/4885 |
| US-12084422-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ORC3, NSUN3, POLR2H | XPO1 2079/4885PIM1 3536/4885PIM2 3862/4885 |
| US-20260035348-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | SARS1, NDUFC2, CLIC1 | XPO1 3609/4885PIM1 3339/4885PIM2 3533/4885 |
| US-12479802-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ORC3, NSUN3, POLR2H | XPO1 2079/4885PIM1 3536/4885PIM2 3862/4885 |
| US-20210309611-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ORC3, NSUN3, POLR2H | XPO1 2079/4885PIM1 3536/4885PIM2 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.